Lisata Therapeutics, Inc.

The momentum for this stock is not very good. Lisata Therapeutics, Inc. is not a good value stock. Lisata Therapeutics, Inc. is not a good growth stock. Lisata Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Lisata Therapeutics, Inc..

News

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Globe Newswire BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ( Lisata or the Company ), a clinical-stage pharmaceutical company developing innovative...\n more…

Lisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinoma

Proactive Investors - UK Lisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinoma...\n more…

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Zolmax Lisata Therapeutics, Inc. (NASDAQ:LSTA - Get Free Report) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 9,800 shares, a decrease...\n more…

HC Wainwright Equities Analysts Raise Earnings Estimates for Lisata Therapeutics, Inc. (NASDAQ:LSTA)

Zolmax Lisata Therapeutics, Inc. (NASDAQ:LSTA - Free Report) - Equities researchers at HC Wainwright raised their Q3 2024 earnings estimates for shares of Lisata Therapeutics in a research report issued...\n more…

LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nLSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post LSTA...\n more…

Lisata Therapeutics coming off strong 2Q performance, CEO says

Proactive Investors - UK Lisata Therapeutics coming off strong 2Q performance, CEO says...\n more…